Bank Of New York Mellon Corp Oncternal Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.86 - $22.2 $15,136 - $390,720	17,600 New	17,600 $17,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $83,179 - $185,371	-118,828 Reduced 87.1%	17,600 $20,000
Q1 2022 May 11, 2022	SELL	$1.37 - $2.43 $4,971 - $8,818	-3,629 Reduced 2.59%	136,428 $190,000
Q4 2021 Feb 11, 2022	BUY	$2.27 - $4.39 $5,166 - $9,991	2,276 Added 1.65%	140,057 $318,000
Q3 2021 Nov 12, 2021	BUY	$3.37 - $4.76 $32,766 - $46,281	9,723 Added 7.59%	137,781 $575,000
Q2 2021 Aug 11, 2021	BUY	$4.75 - $9.39 $524,675 - $1.04 Million	110,458 Added 627.6%	128,058 $608,000
Q1 2021 May 13, 2021	SELL	$4.59 - $9.04 $8,289 - $16,326	-1,806 Reduced 9.31%	17,600 $146,000
Q4 2020 Feb 09, 2021	BUY	$1.51 - $6.3 $3,595 - $15,000	2,381 Added 13.99%	19,406 $95,000
Q2 2019 Aug 12, 2019	BUY	$4.86 - $9.24 $82,741 - $157,311	17,025 New	17,025 $113,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.